Earnings summaries and quarterly performance for ProMIS Neurosciences.
Executive leadership at ProMIS Neurosciences.
Board of directors at ProMIS Neurosciences.
Research analysts covering ProMIS Neurosciences.
Recent press releases and 8-K filings for PMN.
ProMIS Neurosciences Announces Private Placement Financing
PMN
- ProMIS Neurosciences Inc. announced a private placement financing of up to $175 million, with approximately $75 million in upfront gross proceeds before fees and expenses.
- This financing is expected to extend the company's cash runway into 2028 and enable the completion of its landmark Phase 1b Alzheimer's disease clinical study.
- The placement involves the issuance and sale of common shares, common share warrants, and pre-funded warrants, with the closing anticipated on February 3, 2026.
- The financing is co-led by Janus Henderson and Ally Bridge Group, with participation from other new and existing institutional investors, as well as the ProMIS CEO and members of the management team and Board of Directors.
8 days ago
ProMIS Neurosciences Updates on PMN310 Phase 1b Alzheimer's Trial Progress and Timelines
PMN
New Projects/Investments
Guidance Update
- ProMIS Neurosciences' lead compound, PMN310, an amyloid beta monoclonal antibody for Alzheimer's disease, is currently in a Phase 1b study. The company's strategy focuses on selectively targeting low molecular weight toxic oligomers rather than plaque, which is believed to be the primary driver of Alzheimer's progression.
- The Phase 1b Precise AD trial is on track for complete enrollment by the end of 2025. The study targets 128 patients to achieve 100 completers across three doses (5, 10, and 20 mg/kg).
- Interim analysis results from the Phase 1b study are expected in Q2 2026, focusing on safety and biomarkers, while final top-line results, including clinical endpoints, are anticipated in Q4 2026.
- The trial has demonstrated a "superb" safety profile to date, with no significant adverse events (SAEs) or ARIA incidents, even at higher doses. The company aims for ARIA incidence equivalent to placebo levels.
- A decision regarding the pursuit of a subcutaneous (subq) formulation for PMN310 is expected to be made at the time of the interim analysis in Q2 2026.
Dec 2, 2025, 8:25 PM
ProMIS Neurosciences Provides Update on Alzheimer's Clinical Study
PMN
New Projects/Investments
Guidance Update
- ProMIS Neurosciences (PMN) is on track to complete enrollment for its PMN310 Phase I-B clinical study in Alzheimer's patients by the end of 2025.
- The study's lead compound, PMN310, is an amyloid beta monoclonal antibody designed to selectively target low molecular weight toxic oligomers, aiming to avoid the side effects (ARIA) seen with plaque-clearing drugs.
- The company expects an interim analysis focused on safety and biomarkers in Q2 2026, with final top-line results including clinical efficacy expected in Q4 2026.
- To date, the safety profile has been "superb", with the company anticipating ARIA incidents equivalent to placebo levels.
- A decision on pursuing a subcutaneous formulation for PMN310 is likely to be made following the interim analysis in Q2 2026.
Dec 2, 2025, 8:25 PM
ProMIS Neurosciences Provides Update on PMN310 Phase 1b Alzheimer's Trial
PMN
Guidance Update
New Projects/Investments
- ProMIS Neurosciences is on track to complete enrollment for its PMN310 Phase 1b study in Alzheimer's patients by the end of 2025, with a target of 128 patients.
- The company expects an interim analysis in Q2 2026, which will focus on biomarkers and safety, followed by final top-line results in Q4 2026, including clinical endpoints.
- PMN310 is designed to selectively target low molecular weight toxic oligomers of amyloid beta, aiming to avoid the ARIA liability seen with other drugs that clear plaque.
- The safety profile of PMN310 has been described as "superb to date" in the ongoing Phase 1b trial, with expectations of ARIA incidents equivalent to placebo levels.
Dec 2, 2025, 8:25 PM
ProMIS Neurosciences Announces Third Quarter 2025 Financial Results and Corporate Highlights
PMN
Earnings
New Projects/Investments
Guidance Update
- ProMIS Neurosciences reported a loss from operations of $11.8 million for the third quarter ended September 30, 2025, compared to $4.4 million for the same period in 2024, primarily due to expenditures on the PRECISE-AD Phase 1b clinical trial for PMN310.
- As of September 30, 2025, cash and cash equivalents were $15.4 million, an increase from $13.3 million as of December 31, 2024, driven by approximately $21.6 million in gross proceeds from July 2025 transactions.
- The Phase 1b trial in Alzheimer’s disease for PMN310 is over 85% enrolled, with Cohorts 1 and 2 fully enrolled and Cohort 3 well underway, expecting complete enrollment before the end of 2025.
- The company is on track to report 6-month interim data in Q2 2026 and final 12-month top-line results in Q4 2026 for the PMN310 trial.
Nov 12, 2025, 12:05 PM
ProMIS Neurosciences Provides Update on Alzheimer's Candidate PMN 310 Phase 1b Study
PMN
New Projects/Investments
Guidance Update
- ProMIS Neurosciences (PMN) is conducting a robust 100-patient Phase 1b study for its lead Alzheimer's candidate, PMN 310, which is over 90% enrolled.
- Interim analysis data for the PMN 310 study is anticipated in mid-next year, with final top-line results expected by the end of next year.
- PMN 310 is designed to selectively target toxic amyloid beta oligomers, aiming for improved efficacy and a significantly better safety profile by avoiding plaque binding and the associated ARIA liability seen with other treatments.
- The company has received Fast Track Designation from the FDA, and its independent Data Safety Monitoring Board (DSMB) has cleared all dose escalations, indicating a favorable safety profile for PMN 310 to date.
- The Phase 1b study is designed to be robust enough to potentially bypass a Phase 2 trial and move directly into a pivotal Phase 3 study, accelerating time to market and reducing costs.
Nov 10, 2025, 4:00 PM
ProMIS Neurosciences Receives DSMB Approval to Advance Alzheimer's Trial
PMN
New Projects/Investments
- ProMIS Neurosciences Inc. (PMN) received DSMB approval to advance its PMN310 Alzheimer's trial to the third and final dose escalation cohort.
- The Phase 1b PRECISE-AD trial has seen no cases of amyloid-related imaging abnormalities (ARIA) observed to date, with enrollment and dosing for Cohort 3 now underway.
- The trial, expected to enroll 128 patients, remains on track to report 6-month interim data in Q2 2026 and final 12-month top-line results in Q4 2026.
- PMN310 was granted Fast Track designation by the U.S. Food and Drug Administration in July 2025.
Sep 3, 2025, 11:05 AM
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more